ArticlePediatric transplantation2025
Kidney Transplantation in Congenital Heart Disease Patients: What Are the Outcomes?
Article in Pediatric transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCongenital heart disease (CHD) patients experience risks for renal failure, including low cardiac output, exposure to nephrotoxic agents, and surgical interventions. Outcomes of kidney transplantation in CHD patients remain underexplored.
methodsA retrospective review of the Pediatric Health Information System database from 1/1/04-10/30/23. All patients < 18 years who underwent kidney transplantation were included. Multi-organ transplants were excluded. International Classification of Diseases 9th and 10th editions were utilized to identify patients with a diagnosis consistent with CHD.
resultsA total of 7586 patients were identified, with 3109 (41%) female, 3833 (51%) white non-Hispanic, and a median age of 13 [IQR:7-16] years at transplant. A CHD diagnosis was present in 181 (2%). CHD patients were more likely to have mechanical ventilation > 96 h (n = 54 (30%) vs. n = 1264 (17%), p < 0.001) and red blood cell transfusion (n = 48 (27%) vs. n = 1452 (20%, p = 0.026)). On multivariable analysis, CHD was associated with a 9% (95% CI: 2.5-17.1) increase in length of stay (p = 0.007) and was not associated with an increased risk for 30-day readmission (OR: 0.88; CI: 0.62-1.26, p = 0.509). Over a median follow-up of 2.6 [IRQ: 0.7-5.7] years, no difference in re-transplant free survival was evident.
conclusionsCHD patients have increased inhospital resource utilization compared to non-CHD, but no difference in long-term outcomes. However, differences in willingness to transplant cannot be assessed with this data. Further work is needed to better understand the impact of CHD on management decisions and outcomes across the kidney disease continuum.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.